Immupharma (IMM)

 

Latest News

Notification of Full Year Results

RNS Number: 7012F Immupharma PLC 22 May 2017 22 MAY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") NOTIFICATION OF FULL YEAR RESULTS Date: 1 June 2017 ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, confirms that it will be announcing its full year results for the year ended 31 Decembe...

Lupuzor study on track, says ImmuPharma

ImmuPharma's phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupu...

Update on Lupuzor Phase III Study

RNS Number: 3534F Immupharma PLC 17 May 2017 17 MAY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of L...

New Employee Share Option Plan & Grant of Options

RNS Number: 1661B Immupharma PLC 31 March 2017 The following amendments have been made to the ' New Employee Share Option Plan & Grant of Options ' announcement released on 31 March 2017 at 8:33am under RNS No 1493B. The number of Ordinary Shares currently held by Dimitri Dimitriou and Robert Zimmer and their respective percentage holdin...

All News

DateHeadlineSource
22-05-17Notification of Full Year ResultsRNS
17-05-17Lupuzor study on track, says ImmuPharma StockMarketWire
17-05-17Update on Lupuzor Phase III StudyRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
24-03-17ImmuPharma to present at Master Investor ShowRNS
22-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
10-03-17?4.1 Million Fund Raise via Accelerated BookbuildRNS
10-03-17Accelerated Bookbuild for the Issue of EquityRNS
06-03-17Holding(s) in CompanyRNS
17-02-17Holding(s) in CompanyRNS
25-01-17Update on Lupuzor Phase III StudyRNS
24-01-17Change of AdviserRNS
29-12-16Holding(s) in CompanyRNS
22-12-16ImmuPharma completes Lupuzor patient recruitment StockMarketWire
22-12-16Update on Lupuzor Pivotal Phase III StudyRNS
16-11-16ImmuPharma update on cancer compound StockMarketWire
16-11-16Update on Cancer Compound IPP-204106 'Nucant'RNS
09-11-16Holding(s) in CompanyRNS
26-10-16Holding(s) in CompanyRNS
24-10-16ImmuPharma fundraising StockMarketWire
21-10-16Close of Accelerated BookbuildRNS
21-10-16ImmuPharma placing StockMarketWire
21-10-16Proposed Accelerated Bookbuild for Vendor PlacingRNS
30-09-16ImmuPharma losses increase StockMarketWire
30-09-16Half-year ReportRNS
14-09-16ImmuPharma update on Lupuzor study StockMarketWire
14-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
07-09-16ImmuPharma to open new site in Lupuzor study StockMarketWire
07-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
21-07-16Holding(s) in CompanyRNS
20-07-16Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
01-07-16Holding(s) in CompanyRNS
27-06-16Second Price Monitoring ExtnRNS
27-06-16Price Monitoring ExtensionRNS
20-06-16ImmuPharma appoints joint broker StockMarketWire
20-06-16Appointment of Joint BrokerRNS
09-06-16Why are Immupharma plc, Purplebricks Group plc and Roxi Petroleum plc among today’s major movers?Motley Fool

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory